Brand/Generic Settlements Not Necessarily Illegal, DoJ Tells Supreme Court

Payments to generic companies to settle patent challenges under the Hatch-Waxman Act are not necessarily violations of antitrust law, the Office of the Solicitor General says in an amicus curiae brief to the U.S. Supreme Court